mometazon furoat for atopic dermatitis in children

Clicks: 263
ID: 159776
2007
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #1 of 6 articles by views in life sciences in space research

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Atopic dermatitis is one of the most prevalent reasons for skin lesions in the infancy. The medications of the first line therapy for this disease are topic glucocorticosteroids (TGCS). The survey has analyzed the efficiency of a new TGCS — mometazon furoat — for treating atopic dermatitis of children. The action mechanism of this medication is connected with the suppression of proinflammatory cytokinins synthesis (Il6, Il1, TNF). Mometazon furoat has clear anti inflammatory, antipruritic and anti exudative action. The treatment results proved high efficiency of the medication both for noncomplicated atopic dermatitis and for atopic dermatitis complicated with a secondary infection.Key words: atopic dermatitis, topic glucocorticosteroids, therapy, children.
Reference Key
shaipov2007pediatrieskamometazon Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;T.S. Shaipov;L.P. Mazitova
Journal life sciences in space research
Year 2007
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.